Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
Experts say the ACR/AAHKS 2022 guidelines for patients undergoing total hip replacement or total knee replacement have several limitations that limit the effectiveness of their recommendations.
Read Full NewsThe largest randomized study of a multicancer blood test found no reduction in late-stage cancers, while raising new questions about stage shift, mortality benefit, and population screening.
Interim findings from the phase 3 MonumenTAL-3 trial highlight overall and progression-free survival as well as response rates compared with standard therapy.
1.
Video: How to treat kidney disease?
2.
DNA origami offers more accurate imaging in the fight against pancreatic cancer
3.
After targeted agents, a novel bispecific in EGFR-mutant lung cancer improves PFS.
4.
How to keep your prostate healthy and lower your risk of developing serious problems
5.
Why alarm is easing over a rise in pancreatic cancer among the young
1.
Clinical Methods in Hematology and Quality Improvement
2.
Vaso Occlusive Crisis: Understanding the Painful Reality of Sickle Cell Disease
3.
Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion
4.
Case Study: Diagnostic and Therapeutic Challenges in Aplastic Anemia Mimicking Hypoplastic Myelodysplastic Syndrome
5.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
2.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
5.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge